Clinical trial Brightline-1
A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma (Brightline-1 ; 1403-0008)
| Cancers | |
|---|---|
| Organ | sarcome |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2/3 |
| Academic trial | Non |
| Sponsor | Boehringer Ingelheim |
| EudraCT Identifier | 2021-002392-20 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05218499 |
| Last update |